- Home
- RGLS
RGLS
Regulus Therapeutics Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2012 |
| Target Price: | $11.80 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.83 - $2.91 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Regulus Therapeutics Inc. (RGLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hagan Joseph P | RGLS | Chief Executive Officer | Jan 30 '25 | Buy | $1.09 | 50,000 | $54,260.00 | 260,808 | |
| BALTIMORE DAVID | RGLS | Director | Jan 30 '25 | Buy | $1.06 | 19,610 | $20,786.60 | 22,169 | |
| Klassen Preston | RGLS | President & Head of R & D | Jan 13 '25 | Sell | $1.26 | 31,445 | $39,721.32 | 36,055 | |
| CALSADA CRISPINA | RGLS | Chief Financial Officer | Jan 13 '25 | Sell | $1.26 | 43,804 | $55,333.21 | 50,566 | |
| Hagan Joseph P | RGLS | Chief Executive Officer | Jan 13 '25 | Sell | $1.26 | 127,054 | $160,494.61 | 210,808 | |
| Aker Christopher Ray | RGLS | Sr. VP & General Counsel | Jan 13 '25 | Sell | $1.26 | 43,635 | $55,119.73 | 49,546 |
Latest Regulus Therapeutics Inc. News
RGLS Breaking Stock News: Dive into RGLS Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
a day ago
Top Midday Gainers
MT Newswires
a day ago
Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease
PR Newswire
a day ago
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Insider Monkey
11 days ago
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now
Simply Wall St.
13 days ago
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?
Associated Press Finance
15 days ago
Regulus: Q4 Earnings Snapshot
PR Newswire
15 days ago
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Compare RGLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGLS Regulus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.